Literature DB >> 12599085

Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.

W Ripley Ballou1, Jennifer L Reed, William Noble, Neal S Young, Scott Koenig.   

Abstract

A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n=24) received either 2.5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12599085     DOI： 10.1086/368382

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  23 in total

1.  Hereditary spherocytosis; new guidelines.

Authors:  P H B Bolton-Maggs
Journal:  Arch Dis Child       Date:  2004-09       Impact factor: 3.791

Review 2.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

3.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 4.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

5.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 6.  Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development.

Authors:  Piyanki Das; Koustav Chatterjee; Nabanita Roy Chattopadhyay; Tathagata Choudhuri
Journal:  Virusdisease       Date:  2019-03-26

7.  Safety and immunogenicity of a candidate parvovirus B19 vaccine.

Authors:  David I Bernstein; Hana M El Sahly; Wendy A Keitel; Mark Wolff; Gina Simone; Claire Segawa; Susan Wong; Daniel Shelly; Neal S Young; Walla Dempsey
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

8.  Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection.

Authors:  J Mossong; N Hens; V Friederichs; I Davidkin; M Broman; B Litwinska; J Siennicka; A Trzcinska; P VAN Damme; P Beutels; A Vyse; Z Shkedy; M Aerts; M Massari; G Gabutti
Journal:  Epidemiol Infect       Date:  2007-10-24       Impact factor: 2.451

Review 9.  [Viral exanthem].

Authors:  R Fölster-Holst
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

10.  The effects of co-infection with human parvovirus B19 and Plasmodium falciparum on type and degree of anaemia in Ghanaian children.

Authors:  Kwabena Obeng Duedu; Kwamena William Coleman Sagoe; Patrick Ferdinand Ayeh-Kumi; Raymond Bedu Affrim; Theophilus Adiku
Journal:  Asian Pac J Trop Biomed       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.